^
Association details:
| Biomarker: | EGFR exon 19 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + dubermatinib (TP-0903) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The AXL inhibitor, TP-0903, reverses EMT and shows activity in non-small cell lung cancer preclinical models
Published date:
10/12/2022
Excerpt:
The overall response rate (ORR) by investigator is 1 (4.5%) partial response (PR) and 13 (59%) stable disease (SDs), with 6 SDs for >6 months. Disease control rate (DCR) is 64%. One pt with EGFR exon 19 deletion who progressed on osimertinib has an ongoing PR for 3+ years....TP-0903 added to osimertinib in unselected resistant EGFR+ NSCLC patients showed intriguing signals of activity that deserves further investigation, the safety profile was manageable.
